AVXL

NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL).

NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system diseases with high unmet medical needs, today announced that, based on the preliminary vote count provided by its proxy solicitor following the Company's 2026 Annual Meeting of Stockholders (“Annual Meeting”), Anavex stockholders have voted to elect all six of its director nominees – Dr. Jiong Ma, Dr. Peter Donhauser, Dr. Axel Paeger, Mr.

New York, New York--(Newsfile Corp. - September 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Anavex Life Sciences Corp. (NASDAQ: AVXL) resulting from allegations that Anavex may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Anavex securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

NEW YORK, Sept. 21, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Anavex Life Sciences Corp. (NASDAQ: AVXL) resulting from allegations that Anavex may have issued materially misleading business information to the investing public.

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Anavex Life Sciences Corp. (NASDAQ: AVXL) resulting from allegations that Anavex may have issued materially misleading business information to the investing public. So What: If you purchased Anavex securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrange.

-- Believes Anavex Needs New Leadership with Deep Industry Experience and Credible Strategic Plan to Turn the Company Around and Unlock Value for Shareholders – -- Believes Anavex Needs New Leadership with Deep Industry Experience and Credible Strategic Plan to Turn the Company Around and Unlock Value for Shareholders –

-- Proxy advisor recommends voting  “ FOR” two of PVG's director nominees and “AGAINST” two incumbent director nominees including the board's current chair on the GOLD Universal Proxy Card –

Anavex Life Sciences Corp. (AVXL) Discusses Board Misalignment, Leadership Concerns, and Strategic Changes for Company Turnaround Transcript

-- Yet ISS gives Anavex Board a free pass on years of failed governance and shareholder value destruction by supporting the current board's nominees –

ISS Recognizes There is No Case for Change Anavex Urges Stockholders to Follow ISS' Recommendation and Vote “FOR” ALL Six Director Nominees on the WHITE Proxy Card Today NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or “the Company”), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system diseases with high unmet medical needs, today announced that leading independent proxy advisory firm Institutional Shareholder Services (“ISS”) has recommended that Anavex stockholders vote on the WHITE proxy card “FOR” all six of the Company's highly qualified director nominees standing for election at the 2026 Annual Meeting of Stockholders – Dr. Jiong Ma, Dr. Peter Donhauser, Dr. Axel Paeger, Mr.